Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma.
Summary
This study investigates predictive biomarkers for immune checkpoint inhibitor (ICI) response in metastatic urothelial carcinoma. Researchers found that ICI responders exhibited higher tumor mutational burden (TMB) and enriched mutations in genes such as PIK3CA. Functional in vitro and in vivo studies demonstrated that PIK3CA mutations enhance tumor immunogenicity by activating the IRF1-NLRC5-MHC-I axis, thereby improving antigen presentation and CD8+ T-cell cytotoxic response. These findings suggest that PIK3CA mutation could serve as a biomarker to predict ICI sensitivity and represents a novel immune-modulating mechanism.
Analysis
Clinique: This retrospective study of 67 patients with metastatic urothelial carcinoma treated with ICIs suggests that PIK3CA mutations, in addition to high TMB, are predictive biomarkers of response. Although retrospective, the in vitro and in vivo functional validations strengthen the robustness of this finding. Identifying PIK3CA mutation as an immune-modulating factor could justify prospective clinical trials to stratify patients and optimize ICI treatment selection. Clinical impact could be seen in the medium term (3-5 years) if these results are confirmed in larger cohorts. Biomol: The key discovery is that oncogenic PIK3CA mutations enhance tumor immunogenicity by specifically activating the IRF1-NLRC5-MHC-I axis, leading to improved antigen presentation and increased anti-tumor immune response. The techniques employed are diverse and robust, including targeted next-generation sequencing (440-gene panel), functional studies on cell lines (PBMC co-culture, gene knockdown/overexpression), molecular analyses (qPCR, immunofluorescence, Western blot), and syngeneic murine models with CRISPR/Cas9 gene editing. These methods allowed for dissecting the underlying molecular mechanism, demonstrating strong translational validity. Bioinfo: The study utilized a targeted next-generation sequencing panel of 440 genes to analyze genomic alterations. Bioinformatic analysis correlated PIK3CA mutations with elevated TMB not only in the urothelial carcinoma cohort but also across multiple TCGA pan-cancer, breast, and colorectal cohorts, reinforcing the generalizability of the observation. The integration of these data with clinical and functional results was crucial for identifying PIK3CA as an immune modulator.